Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Total Non-Current Liabilities (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $257.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 58.93% year-over-year to $257.0 million, compared with a TTM value of $257.0 million through Sep 2025, down 58.93%, and an annual FY2025 reading of $18.4 million, up 19.96% over the prior year.
  • Total Non-Current Liabilities was $257.0 million for Q3 2025 at Roivant Sciences, up from $216.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q4 2024 and bottomed at -$2.4 billion in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $413.0 million, with a median of $599.5 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 128.41% in 2022, then plummeted 97.99% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $543.9 million in 2021, then soared by 38.68% to $754.3 million in 2022, then decreased by 11.36% to $668.6 million in 2023, then soared by 85.04% to $1.2 billion in 2024, then tumbled by 79.23% to $257.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ROIV at $257.0 million in Q3 2025, $216.5 million in Q2 2025, and $18.4 million in Q1 2025.